A Study of Bemotuzumab Plus Chemotherapy and Anlotinib Induction Followed by Bemotuzumab, Anlotinib and Consolidative Thoracic Radiotherapy in Extensive-Stage Small Cell Lung Cancer

Phase 2 Recruiting 25 enrolled Tianjin Medical University Cancer Institute and Hospital

NaSingle-groupOpen-labelTreatment

Summary

This is a phase II study evaluating a new combination therapy for untreated extensive-stage small cell lung cancer. The treatment involves an initial phase with the drug Bemotuzumab plus standard chemotherapy and anlotinib, followed by a phase combining Bemotuzumab, anlotinib, and chest radiation. The primary objectives are to assess the efficacy of this approach in delaying cancer growth (progression-free survival) and to evaluate its safety in approximately 25 patients.

Timeline

Start: 2026-02-01
Primary completion: 2027-01-01
Completion: 2028-01-01

Publications

Zhou Y, Zhu H, Yang S, Liu J, Yu M, Sun J, Yang C, Cui Y, Liu N. Consolidation thoracic radiotherapy following quadruple induction with benmelstobart, anlotinib, and chemotherapy for extensive-stage small cell lung cancer: rationale and protocol of a phase II study. Transl Lung Cancer Res. 2026 Jun 30;15(6):181. doi: 10.21037/tlcr-2026-1-0114. Epub 2026 May 15.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Bemotuzumab	Unknown	1200 mg	Intravenous
Subject	Catequentinib	Small molecule	12 mg	Oral
Background	Carboplatin	Small molecule	5 unknown	—
Background	Cisplatin	Other / unclassified	75 mg/m2	—
Background	Cisplatin	Other / unclassified	80 mg/m2	—
Background	Etoposide	Small molecule	100 mg/m2	Intravenous

A Study of Bemotuzumab Plus Chemotherapy and Anlotinib Induction Followed by Bemotuzumab, Anlotinib and Consolidative Thoracic Radiotherapy in Extensive-Stage Small Cell Lung Cancer

Summary

Timeline

Publications

Drugs

Indications